Developing novel diagnostics to optimize central nervous system disease management. Currently in the process of finalizing development of the first-of-its kind, blood-based laboratory diagnostic for epilepsy. Expected commercialization in 2025/26

TAXIS has been expanding its portfolio of drug candidates by focusing on the disruption of the foundation of bacterial cell wall architecture (e.g., construction, maintenance and growth) to address elemental drug resistance mechanisms in our efforts to reduce, or possibly eliminate, the threat of current and emerging antibiotic resistance across a wide-range of infectious diseases.Our proprietary molecular chemistry is designed to treat patients suffering from antibiotic-resistant strains of bacteria by enabling re-use of many of the most widely-prescribed generic antibiotics. TAXIS' novel technology resurrects the activity of these currently marketed drugs including cephalosporins, monobactams, tetracyclines, sulfanomides, fluoroquinolones and macrolides.The technology is licensed out of Rutgers, The State University of NJ.

Identify angel investment opportunities, perform due diligence and syndicate approved deals

Evogen is a discovery-stage, medical diagnostics venture focused on novel, rapid assays with significant clinical relevance in neurologic, anti-inflammatory and oncology disease management.